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Abstract
Background: Sex ratio is an important indicator of development. Despite all the measures undertaken for improvement,
it remains an issue of concern in India, with Haryana having a very low sex ratio in the country. Studies have
been conducted indicating that consumption of indigenous drugs used for sex selection (SSD) could be
strongly associated with adverse effects on the foetal development, including congenital malformations.
Some samples of SSDs were collected from parts of North India and analysed in a standard laboratory for its components.
Methods: Thirty SSDs used by the local community were procured from various sources in north India through a
rigorous process of collection. These were subjected to laboratory tests to investigate the presence of phytoestrogen
and testosterone. Following sample extraction, thin layer chromatography and high performance liquid chromatography
were carried out for analysing phytoestrogen content.
Results: SSDs were available in various forms such as powder, tablets, mostly from faith healers. Around 87 % of the
samples collected from sources like doctors, quacks and faith healers were to be taken by the pregnant women after
conception; 63 % drugs were strongly positive for phytoestrogens (genistein, daidzein, formononetin) and 20 % drugs
were positive for testosterone. The average dose of the components as calculated after analyses was as follows:
daidzein - 14.1 mg/g sample, genistein - 8.6 mg/g sample, formononetin - 5 mg/g sample.
Conclusion: These SSDs could be potentially detrimental to the growth and development of the foetus. This is likely
to have implications on the health of the community. In view of the results obtained in our study, we strongly attest
the importance in curbing this harmful practice by banning the supply of the drugs as well as by advocating behavioural
changes in the community.
Background
Sex ratio has been an important indicator of develop-
ment since decades. Census data for the past 100 years
have shown a skewed pattern of the sex ratio in favour
of males. Traditionally, it has been observed that there is
a preference for sons in India. Various means to have a
son include going through multiple pregnancies till a
son is born, sex selective abortions, pre-conceptional
techniques and post-conceptional intake of drugs to
beget a male child. This has nation-wide implications,
especially for issues such as female foeticide and health
care for the living girls. The PNDT Act (Pre Natal Diag-
nostic Technique) brought into force since 1994 banned
the detection of sex of the foetus and has been a useful
step towards curbing female foeticide. A subsequent
amendment in 2002 brought pre-conceptional sex selec-
tion techniques also into its fold since people were resort-
ing to pre-conceptional methods, thereby changing the
PNDT Act to PCPNDT Act (Pre Conception, Pre Natal
Diagnostic Technique). Despite all these measures, sex ra-
tio continues to be a concern. Haryana, an Indian state,
has one of the lowest sex ratios (879 females per 1000
males) in comparison to the national figure of 933 females
per 1000 males [1, 2].
Besides sex selective abortions, several indigenous
methods are in vogue for giving birth to a male child.
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Some of these include consumption of special diet
before and after conception, timing and date of sexual
intercourse (even dates such as 2nd, 4th, 6th of the
month for male offspring or full moon/no moon) and
reciting chants. The rituals adopted for conception of
healthy male child is described as “Pumsavana karma.”
Intake of indigenous medicines for sex selection in India
as well as the West is also documented [3, 4]. Anecdotal
reports and research findings highlighting this practice
have found their place in newspapers over the last two
decades. In 1991, Government of Gujarat, India, banned
the manufacture and sale of Select, a drug which was
claimed to produce a male foetus if a pregnant woman con-
sumed it for 45 days after her last menstrual period [5].
Consumption of indigenous medicines used for sex
selection, also known as Sex Selection Drugs (SSD) dur-
ing the first trimester of pregnancy is prevalent in cer-
tain parts of the country [3, 6, 7]. A case—control study
was undertaken in the state of Haryana, India recently
to investigate the risk factors for congenital malforma-
tions. Data regarding congenital malformations and the
risk factors were collected from across all 21 districts of
the state. Factors such as having more than two living
children and the intake of sex selection drugs were
found to be strongly associated with congenital malfor-
mations [8]. Similar reports were observed in an earlier
hospital-based study [9]. It is important to note that
SSDs are consumed during the most critical period of
development of the embryo. To probe further into the
details of the drugs consumed, some samples of SSDs
were collected from various parts of North India and
laboratory analyses were carried out to investigate the
presence of certain components which might have an
effect on the development of the embryo. The results of
the analyses are presented here.
Methods
This study was undertaken as a part of a larger case—
control study on “Risk factors of congenital malforma-
tions in Haryana” described elsewhere [8].
Collection of SSDs
In order to get information about the drugs, understand
the methods of procuring them as well as collecting the
drugs for analyses, the research team spoke to women
who had delivered and also various genres of people
including rickshaw pullers, drivers, cobblers and com-
moners in different areas of Haryana. Confidentiality
was maintained throughout the study. It was indeed a
tough task for the team to extract information about the
suppliers of these drugs, since people maintained secrecy
on this sensitive issue. It was observed that asking direct
questions to the respondents would not help in extract-
ing correct information, so information was gathered in
a more informal and indirect manner. Finally, based on
the information gained thus, the team managed to pro-
cure samples from various districts across the states of
North India. Samples were collected and stored in poly-
propylene bottles in moisture-free conditions and trans-
ferred to the laboratory at Department of Biotechnology,
Thapar University, Patiala for analyses within 17–24 h.
They were stored in dark at 28 °C.
Biochemical analysis of SSDs
A previous study had indicated that the SSDs contain
steroids and testosterone [4]. The focus in the current
research for laboratory investigations was restricted to
testosterone and phytoestrogens in the drugs, since these
are known to be the most commonly associated compo-
nents to affect the development of the embryo. Owing
to the high cost of the test kits for testosterone, this com-
ponent was not tested in all of the procured samples.
Phytoestrogen, however, was tested in all the procured
samples. The following methods were used for analyses:
1. Sample extraction was done as proposed by Beck in
1964 [10]. All extracts were coded and analysed
further.
2. Thin layer chromatography (TLC): The solvent
system used was Chloroform/methanol (89: 11, v/v)
on silica gel plates. All phytoestrogen standards
(Sigma, Mo USA) could be visualized as blue-white
fluorescent spots under UV light (257 nm). The
experiment was repeated at least thrice to confirm
initial authentication.
3. Identification and final quantitation High
performance liquid chromatography (HPLC): All
HPLC analyses were performed using a Reverse
phase column (C-18) octadecylsilane (4 mm I.D ×
30 cm). Detector used was UV–VIS variable
wavelength detector. Column temperature was
maintained at 30 °C. Detection of phytoestrogens
was made at 254 nm (optical bandwidth 8 nm).
Separation was achieved by using a linear methanol—
water gradient system at a flow rate of 1.0 ml/min. Metha-
nol and water reservoirs each contained 1 % glacial acetic
acid (v/v) and 0.01 M ammonium acetate HPLC grade by
Casteele et al. [11].
The gradient was programmed to increase from 53 to
58 % reservoir B (methanol) over 30 min. Preliminary
peak identification was based on a comparison of reten-
tion times of phytoestrogens standards and unknown
peaks in the sample extracts.
The preliminary characterization of phytoesterogens
by TLC in the drug samples was confirmed by HPLC
analysis. A quantitation from HPLC peak area indicated
the approximate quantities of each phytoestrogen. The
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results are presented as the proportion of samples
detected positive for phytoestrogens and testosterone.
Samples found strongly positive for these ingredients
were subjected to further analyses and the average doses
of each phytoestrogen consumed were calculated. Quan-
tification of testosterone was however, not done.
Ethical considerations
The study was approved by Institutional Ethics Commit-
tee of Indian Institute of Public Health, Delhi. The par-
ticipants of the study were mostly women who had
delivered. Written consent was taken from them before
interviewing after explaining to them about the study.
Results
A total of 30 samples were collected from various sources
ranging from doctors/quacks to faith healers in North
India.
The sources provided instructions for varied methods
of consumption of the drugs. One such instruction
included the consumption of this drug with cow’s milk,
to be consumed early morning without looking at any
other female.
These drugs were given to the pregnant lady in specific
doses to be consumed during the first trimester after con-
firmation of pregnancy, particularly during 6–10 weeks of
pregnancy. They were available in different forms for con-
sumption. Some drugs were to be taken in the form of a
powder; some were in the form of tablets. In some cases,
fruits injected with some medicines were also given. Some
even gave a piece of paper with text written on it in a par-
ticular kind of ink to the pregnant lady for consumption.
This paper was to be consumed with cow’s milk. These
drugs, famous for ensuring the birth of a male child upon
consumption, are known locally as “sau badalne ki
dawai”. Some of these are available at a chemist’s or a gro-
cer’s shop, with faith healers and local villagers. Rithaphal,
Majuphal, Shivalingi are some of the common ingredi-
ents. These drugs are usually to be taken for 3–5 days or
sometimes even for 21 days.
Out of the 30 samples collected, 26 (87 %) were sup-
posed to be taken by women post-conception, three
were to be consumed by males pre-conception and one
by both the partners prior to conception. Nineteen sam-
ples (63 %) were strongly positive for all phytoestrogens
(genistein, daidzein, formononetin). (Figures 1, 2) Testos-
terone was detected in three out of the 15 samples ana-
lysed for testosterone.
Quantitation of each phytoestrogen present was ana-
lysed from HPLC reports (Fig. 3, Table 1) An average
dose was calculated thereafter based on this data and
were as follows: daidzein: 14.10 mg/g sample, genistein:
8.52 mg/g sample, formononetin: 5.09 mg/g sample. The
average weight of each sample was 10 g to be consumed
Fig. 1 Thin layer chromatography Spot of daidzein extracted from
sex selection drugs
Fig. 2 Thin layer chromatography Spot of different phytoestrogens
extracted from sex selection drugs
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over a period of few days ranging from 3 to 21 days
and hence daily dose was difficult to calculate. However,
the total quantity to be consumed represents a ten-fold
increase over that recommended for dietary intake
[12, 13].
Discussion
Majority of the samples of SSDs collected in the study
contained different phytoestrogens (daidzein, genistein
and formononetin) in quantities that could be potentially
detrimental to the growth and development of the
embryo.
Phytoestrogens are plant derived edible items which
show estrogen-like properties and are now recognized as
endocrine disruptor compounds (EDCs). They can act as
estrogenic agonists or antagonists capable of interfering
with the synthesis, secretion and elimination of natural
hormones in the body [14, 15]. Studies indicate that
human embryos and foetuses are exposed to phyestro-
gens and testosterone when mothers consume them dur-
ing pregnancy [16–18]. Phytoestrogenic substances have
shown to cross placental barrier and exposure of the
embryo and foetus is directly related to maternal serum
circulating levels of phytoestrogen [18–21]. Also, it is
suggested that metabolic and/or excretion rates of phy-
toestrogens are different between mother and foetus and
once phytoestrogens are transferred to the embryo and
foetus, they tend to stay in foetal circulation longer than
maternal circulation [21]. Animal studies indicate that
testosterone too can cross the placental barrier [22–24].
It is extremely difficult to examine the effects of phy-
toestrogens or testosterone on human development and
reproduction for ethical reasons. Evidence for concern
emerges from laboratory based animal studies such as on
rodents and to a lesser extent in primates. The observed
effects can reliably predict what is likely to happen in
humans [14].
Organogenesis occurs during 5–8 weeks of gestation
in humans. Any insult during this period (including
intake of phytoestrogens) can result in congenital mal-
formations [25]. Sexual differentiation occurs between
week 5 and 19 of pregnancy. Evidence on its probable
effect can be extrapolated from studies in rodents. In
them, sexual differentiation occurs from gestational days
12–20 [26]. Despite the differences in the periods when
such alterations affect reproductive and brain structures
and functions, the outcomes are largely consistent across
species [27]. SSDs are consumed during 6–10 weeks of
pregnancy which is a very critical period during the
development of a foetus.
Although phytoestrogens mimic the effects of estradiol,
their effects can produce estrogenic or anti-estrogenic
effects depending on the phytoestrogen-estrogen ratio in
the body. This partly explains why estrogenic effects pre-
dominate in livestock, whose estradiol plasma concentra-
tions are relatively low. In contrast, anti-estrogenic effects
are reported mainly in humans in which estrogen plasma
levels are relatively high [28].
An adult woman can regulate the level of endogenous
hormone production even when she is exposed to an
exogenous phytoestrogen because of a mature hypothal-
amic pituitary gonadal (HPG) axis [29]. In embryonic
life, when the reproductive system is developing, andro-
genic and estrogenic hormones can exert ‘organizational’
effects that permanently shape the reproductive system
and its function. Thereafter, adjustments to the exposure
of exogenous hormones cannot be made and it can lead
to adverse effects of target organs. Secondly, inappropri-
ate exposures can permanently alter the sensitivity to
hormonal signals and alter the function of HPG axis
across the lifespan. During puberty and adulthood, the
same hormones exert ‘activational’ and ‘functional’ effects
on a ‘pre-formed’ reproductive system [14, 26].
Early exposure of female embryo and foetus to phy-
toestrogens has also been associated with premature
Fig. 3 HPLC chromatogram of daidzein extracted from sex selection drugs
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thelarche, and breast cancer risks [30]. Acceleration of
vaginal opening, altered oestrous cycles thereby advan-
cing pubertal onset, a decline in fertility are some of the
effects reported from exposure of animals to phytoestro-
gens during neonatal period [14, 31, 32]. On the other
hand, exposure to testosterone can masculinize female
offsprings [33–37]. What is important to note here is
that even a single episode of exposure during this critical
period can be harmful [27]. Early exposure of a male
embryo and foetus to phytoestrogens disrupts the balance
between androgen and estrogen and can impact the de-
gree of masculinization of male foetus [18, 26]. The
more severe the interference, the more severe is the
manifestation, with complete lack of masculinization
(i.e. genotypic male with female genitalia) representing
the most extreme consequence whereas hypospadias
and cryptorchidism represent progressively milder con-
sequences [38–41]. Animal experiments have shown
that all testicular dysgenesis syndrome except testicular
cancer can be induced by exposure of embryo to anti
androgenic compounds [42].
Exposure of a male embryo and foetus to testosterone
can negatively impact the reproductive development in
terms of reduced sperm count and motility [34, 43, 44].
A study on guinea pigs also highlighted that excess of
testosterone during pregnancy can produce hermaphrodites
[45]. Prenatal testosterone also leads to infertility, obesity,
intrauterine growth retardation and insulin resistance in
adulthood [46–48]. With less interference, no obvious con-
sequences may be evident at birth and may manifest only
in adulthood.
Although sexual differentiation occurs in-utero among
humans and rodents, sexual differentiation of the brain
(which is dependent on androgens and estrogens) occurs
in-utero in humans (between 12 and 24 weeks), but dur-
ing the neonatal period in rodents (few days before birth
till 10 days after birth) [49]. Early sexual differentiation
of the developing brain is vulnerable to endocrine disrup-
tion by phytoestrogens which modify the organization of
sexually differentiated neural pathways.
Testosterone and estradiol serve as the most important
factors to establish permanent sex differences in brain
organization [50]. The size of the sexually dimorphic
nucleus of the pre-optic area (SDN) of the brain is larger
in males than females and this is largely associated with
sexual partner preference [18]. Exposure of male rats to
resveratrol (estrogen) during neonatal period has been
shown to be associated with smaller size of SDN and
reduced socio-sexual behaviour in adulthood. Exposure to
testosterone is also known to suppress female behaviour
of the foetus in rats [27, 33, 36, 51].
Effects of endocrine disruption in the developing
foetus are likely to be subtle and not readily apparent at
birth, a lesson learnt from the disastrous case of DES
(diethylstilbestrol). DES, a synthetic estrogen prescribed
to prevent miscarriage ultimately turned out to be a cause
of vaginal dysplasia, cervical adenosis and malformations
of uterus and cervix. It is therefore important to consider
the ‘critical windows of exposure’ when attempting to pre-
dict potential consequences of human exposure to endo-
crine disruptors like phytoestrogens [52–54].
The findings of the laboratory tests warrant further
detailed analyses of larger numbers of samples and ani-
mal studies to explore the possible toxic effects of these









1 1.00 8.80 6.00 Not done
2 13.00 8.70 5.00 Not done
3 13.00 8.50 5.00 Not done
4 15.00 8.50 4.80 +++
5 15.00 8.60 4.80 +++
6 14.75 8.80 5.20 +++
7 14.30 9.20 5.40 ±
8 14.80 9.00 5.32 ±
9 14.78 8.80 5.00 ±
10 14.60 8.80 4.87 ±
11 15.40 8.40 4.88 ±
12 15.03 8.60 5.20 ±
13 16.20 9.00 5.40 ±
14 15.20 8.60 6.35 ±
15 15.30 8.70 6.00 ±
16 16.00 8.60 6.12 ±
17 15.00 8.50 5.00 ±
18 16.00 8.50 5.00 ±
19 15.00 9.00 4.89 Not done
20 15.00 9.20 5.40 Not done
21 14.88 9.10 5.00 Not done
22 14.90 8.88 5.10 Not done
23 14.60 8.70 4.93 Not done
24 15.02 8.00 5.20 Not done
25 15.40 8.04 5.10 Not done
26 15.70 7.93 4.80 Not done
27 15.50 8.40 4.20 Not done
28 15.50 8.00 4.50 Not done
29 9.67 7.30 4.30 Not done
30 7.33 6.3 3.8 Not done
Median (mg/g) 15 8.6 5
Mean (mg/g) 14.10 8.52 5.09
SD 3.01 0.58 0.53
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components. Only a small number of samples were avail-
able for the analyses; a larger number with representation
of more areas across North India, from different sources
would have benefitted the results and their implications
on the harmful practice of consumption of SSDs. Also, the
analyses were done to test for presence of phytoestrogens
and testosterone only, owing to their known effect on the
development of the embryo. However, there might be other
components in the drugs that might have had an effect on
the embryonic development and growth; these could not
be analysed due to logistic and financial constraints. Despite
the limitations of the study, the results of the analyses prov-
ing the presence of fairly large proportions of phytoestro-
gens and testosterone in the drugs substantiate the need to
curb this harmful practice for the benefit of the society at
large. The results obtained from the analyses are reliable
since the analyses were conducted by an experienced pro-
fessional, using standardized methods at a reputed labora-
tory in North India.
Intake of SSD is a harmful practice quite prevalent in
North India. It has been observed largely that these drugs
are prescribed by faith healers and illegal practitioners
largely, who knowingly or unknowingly, engage in not
only an unethical, but a very risky procedure for the pa-
tients and the growing embryo. It is imperative that this
dangerous practice be relinquished at the earliest. The
availability of such drugs in local chemist shops, and with
faith healers can be monitored through rigorous checks
with the involvement of sectors other than health.
Banning the supply of these drugs will only solve part
of the problem. In Indian communities, there are certain
deep-rooted cultural and social customs which have
evolved over the years. Hindu scriptures mention that if
a son sets fire to the funeral pyre for his parents, they
would be released from the travails of this world and
their soul would enter heaven. The dowry system of giv-
ing gifts to the daughter and her in-law’s family at the
time of her marriage, still prevalent in many parts of the
country, is another social tradition [3]. These traditions
and rituals are considered as normal practice and behav-
iour, making them that much more difficult to curb. Tra-
ditions like these increase the demand for a male child
among these communities. It is therefore prudent to bring
about a positive change in the attitudes and behaviours of
the community towards the female child. Various innova-
tive schemes have been launched at the Central and State
levels to highlight this important social issue and provide
more support to a girl child. More needs to be done for
long term gains at the community level. Making the
implementation of PCPNDT Act more stringent at all
levels, with punitive action taken against those who
violate this law within the public as well as private
health systems can be one of the steps in this direc-
tion. Behaviour change communication programs should
be planned and implemented at the community level, tar-
geting families, to change their mind-set regarding these
traditions and practices. Although this will take time to be
widely accepted, in the long run these interventions will
help in stopping female foeticide, and in improving the
status of female children in Indian communities.
Conclusion
Son preference is a phenomenon that we are grappling
with in India. SSDs are consumed during the first tri-
mester of pregnancy to have a male baby. Consumption
of such drugs is dangerous and detrimental to the
growth and development of the embryo since these con-
tain phytoestrogens and testosterone in amounts beyond
the acceptable quantities. This is likely to have long term
implications on the health of the community. It is import-
ant to inform the community of the harms that these
practices can cause in the long run.
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